What Is the Safest Drug for Rheumatoid Arthritis Pain? A Clear Guide

For most people with rheumatoid arthritis, methotrexate is the safest starting point for pain control. Major guidelines from EULAR, ACR, and NICE all put it first. It has decades of real-world safety data, costs less than newer drugs, and genuinely reduces joint swelling and damage. When methotrexate controls the disease well, pain follows. That's the core logic behind every RA treatment decision.

When methotrexate alone isn't enough, TNF inhibitors like etanercept or adalimumab are the next safest step. JAK inhibitors work well but carry a different risk profile that makes them a later choice for most patients, especially older adults. The rest of this article explains why, and what the evidence actually shows about each option.

Why Does the Safest Drug Depend on the Person?

RA pain comes from chronic joint swelling driven by immune chemicals called cytokines, particularly TNF-alpha and IL-6. These same chemicals accelerate heart disease, raise infection risk, and wear down the immune system over time. Uncontrolled RA is itself dangerous. So the safest drug isn't the mildest one. It's the one that controls the disease well enough to reduce those risks while adding the fewest new ones.

Age, other health conditions, and past treatments all shift that calculation. A 40-year-old with no heart disease history has a different risk profile than a 70-year-old who smokes and has had a prior blood clot. What's safest for one person may not be the right call for another.

What Are the Safest Long-Term Medications for Rheumatoid Arthritis?

Conventional synthetic DMARDs sit at the top of the most successful treatment for rheumatoid arthritis. Methotrexate leads this group. Its side effects, mainly liver enzyme changes, nausea, and rare lung problems, are well understood and manageable with regular blood monitoring. Doctors have been using it for decades and know exactly what to watch for.

Hydroxychloroquine and sulfasalazine are often added to methotrexate in a combination called triple therapy. Both have long safety records. Hydroxychloroquine in particular has a very low serious side effect rate, though it requires periodic eye checks to catch a rare retinal problem early.

When these conventional drugs fail to control the disease after three to six months of optimised treatment, biologic DMARDs become the next safest step. A 2023 EULAR systematic review of 59 studies confirmed that biologic DMARDs carry higher serious infection risk than conventional synthetic DMARDs, but that risk is manageable with screening and monitoring. Among biologics, TNF inhibitors have the longest real-world safety record and are typically chosen first.

IL-6 inhibitors like tocilizumab and sarilumab are another biologic option. A 2025 real-world cohort study of over 179,000 RA patients found that IL-6 inhibitors showed a 27% lower cancer risk compared to abatacept, a finding that may influence prescribing decisions for patients with specific cancer risk factors. That said, IL-6 inhibitors raise cholesterol levels and carry their own infection risks, so the benefit has to be weighed against the full picture.

Are Biologics Safe for Treating Rheumatoid Arthritis Pain?

Yes, biologics are considered safe for most RA patients when used with proper screening and monitoring. They aren't risk-free, but the risks are known and manageable.

The main concern with biologics is infection. Because they suppress parts of the immune system, patients are more vulnerable to bacterial infections, tuberculosis reactivation, and opportunistic infections. Before starting any biologic, doctors screen for latent TB, hepatitis B, and other conditions. Patients also need to stay current on vaccines, particularly shingles and flu, before starting treatment.

Cancer risk across biologic classes looks broadly similar. The 2023 EULAR review found no significant difference in cancer risk between biologic DMARDs and tofacitinib, and no major difference in serious cardiovascular events either. The 2025 cohort study added nuance by showing IL-6 inhibitors may carry a modest cancer risk advantage over abatacept, but this finding needs further confirmation before it changes standard practice.

In my experience reading through the clinical literature, the biologics with the most reassuring long-term data are the TNF inhibitors. They've been used since the late 1990s, and the safety signals are well characterised. Abatacept and rituximab are solid alternatives for patients who can't tolerate TNF inhibitors or have specific contraindications.

Is It Safe to Take NSAIDs Every Day for Rheumatoid Arthritis?

No. Daily NSAID use carries real risks that accumulate over time, and it doesn't address the underlying disease process.

NSAIDs like ibuprofen and naproxen reduce pain and inflammation short-term, but they don't slow joint damage. Used daily over months or years, they raise the risk of stomach ulcers and bleeding, kidney damage, and cardiovascular events. The cardiovascular risk is particularly relevant for RA patients, who already have elevated heart disease risk from the disease itself.

COX-2 inhibitors like celecoxib are easier on the stomach than traditional NSAIDs but carry similar cardiovascular concerns. They're useful for short-term flare management or as a bridge while waiting for DMARDs to take effect, but they're not a long-term solution.

If someone is relying on daily NSAIDs to manage RA pain, that's usually a sign the underlying disease isn't well controlled. The right move is to reassess the DMARD regimen, not to keep taking NSAIDs indefinitely.

What Pain Relief Options Are Safest for Older Adults with Rheumatoid Arthritis?

Older adults need a more careful approach because the risk profile of every drug class shifts with age.

Methotrexate remains a reasonable first choice for older adults, but kidney function needs to be checked before starting and monitored regularly, since the drug clears through the kidneys and reduced kidney function raises toxicity risk. Dose adjustments are often needed.

Among biologics, abatacept has shown a relatively favourable safety profile in older patients in several observational studies. TNF inhibitors are also used widely in this age group, though infection risk is higher in older adults generally.

JAK inhibitors require the most caution in older adults. The FDA and EMA have both issued warnings that JAK inhibitors should be reserved for patients who haven't responded to biologics, and used with particular care in patients over 65, those with a history of heart disease, stroke, blood clots, or cancer, and those who smoke. The 2020 review of JAK inhibitor safety flagged a possible increased risk of blood clots and pulmonary embolism with tofacitinib and baricitinib, and while the magnitude of that risk is still being studied, the signal is real enough to warrant caution.

For pain specifically, low-dose corticosteroids like prednisone are sometimes used short-term in older adults during flares. They work quickly but carry significant long-term risks including bone loss, blood sugar elevation, and increased infection risk. They're a bridge, not a foundation.

Can Rheumatoid Arthritis Pain Be Managed Without Strong Medications?

Non-drug approaches can meaningfully reduce RA pain, but they work best alongside medication, not instead of it.

Exercise is the most evidence-backed non-drug option. Supervised resistance training and aerobic exercise reduce pain, improve joint function, and lower cardiovascular risk. What I found in reviewing the research is that many RA patients avoid exercise out of fear of making their joints worse, but the evidence consistently shows the opposite. Movement, done correctly, protects joints over time.

Working with an NDIS personal trainer or exercise physiologist who understands inflammatory conditions can make a real difference here. For people in Melbourne managing RA alongside a disability or chronic condition, structured exercise support through programs like those at BetterStart's NDIS personal training service can help build a safe, progressive routine that complements medical treatment.

Other non-drug approaches with reasonable evidence include heat and cold therapy for symptom relief, occupational therapy to protect joints during daily tasks, and dietary changes like increasing omega-3 intake. These don't replace DMARDs, but they reduce the total pain burden and can lower the dose of medication needed to stay comfortable.

Psychological support also matters. Chronic pain changes how the nervous system processes signals, and cognitive behavioural therapy has shown measurable pain reduction in RA patients in clinical trials. It's underused.

What About JAK Inhibitors, Are They Safe?

JAK inhibitors are effective and convenient as oral pills, but they sit lower on the safety ranking than methotrexate or TNF inhibitors for most patients.

The shingles risk is the clearest concern. The 2023 EULAR review found herpes zoster infections occurred at roughly 3.66 times the rate seen with conventional DMARDs, and 1.9 to 2.3 times the rate seen with biologic DMARDs. Getting the shingles vaccine before starting a JAK inhibitor is strongly recommended.

The cardiovascular and clotting signals are less clear but real enough to influence prescribing. Long-term safety data suggest overall safety is broadly similar to biologics, but the possible blood clot risk with tofacitinib and baricitinib remains a concern that hasn't been fully resolved. Cardiovascular safety of these drugs is also affected by their impact on lipid metabolism, which is separate from their anti-inflammatory effects.

For younger patients without heart disease risk factors who strongly prefer an oral medication and haven't responded to methotrexate, JAK inhibitors are a reasonable option after a thorough conversation with their rheumatologist. For older patients or those with cardiovascular risk factors, they should come after biologics have been tried.

How Does Cardiovascular Risk Factor Into the Decision?

RA itself raises heart disease risk significantly, and this has to be part of every treatment decision. Effective disease control reduces that risk in proportion to how well the drug suppresses inflammation. But the drug's mechanism also matters independently.

Biologic DMARDs and JAK inhibitors both affect how the body handles fats and blood sugar, which influences cardiovascular risk beyond their anti-inflammatory effects. IL-6 inhibitors, for example, raise LDL cholesterol, which needs to be monitored and sometimes treated. TNF inhibitors have a more neutral effect on lipids.

The practical takeaway is that cardiovascular risk management in RA isn't just about picking the right drug. It also means treating high blood pressure, managing cholesterol, not smoking, and staying physically active. The drug is one piece of a larger picture.

FAQ

Is methotrexate safe to take long-term?

Yes, for most patients. The main risks are liver toxicity and, rarely, lung problems. Regular blood tests catch liver enzyme changes early. Most people tolerate it well for years with proper monitoring.

Which biologic has the best safety record?

TNF inhibitors have the longest real-world safety data, going back to the late 1990s. Etanercept and adalimumab are the most widely studied. Their risk profile is well understood.

Can I stop taking RA medication if my pain goes away?

No. Pain relief means the drug is working, not that the disease is gone. Stopping medication usually leads to a flare. Any changes to treatment should be made with a rheumatologist.

Are there natural alternatives to RA drugs?

Some supplements like fish oil have modest anti-inflammatory effects, but none replace DMARDs for controlling joint damage. Exercise, diet, and stress management support treatment but don't substitute for it.

How long does it take for RA medications to reduce pain?

Methotrexate typically takes six to twelve weeks to show full effect. Biologics often work faster, sometimes within two to four weeks. NSAIDs and corticosteroids work within days but don't address the underlying disease.

Should I get vaccinated before starting a biologic or JAK inhibitor?

Yes. Live vaccines can't be given once you start most biologics or JAK inhibitors. Get the shingles vaccine, flu vaccine, and any other recommended vaccines before starting treatment.

The One Thing to Take Away

Start with methotrexate, optimise it with your rheumatologist, and only move to biologics or JAK inhibitors if the disease stays active after three to six months. Pain relief in RA follows disease control. The drug that controls the swelling most effectively with the fewest serious side effects for your specific situation is the safest one. That answer changes with age, health history, and how the disease responds. Review it regularly with your doctor rather than treating it as a one-time decision.

About the author

John Carter

Undergraduate degree in mathematics/statistics from the University of Melbourne. PhD in Statistics from Harvard University

I'm a quantitative scientist with a deep passion for improving health outcomes through rigorous statistical methods and data-driven decision-making.

Connect on LinkedIn →